| Budget Amount *help |
¥13,000,000 (Direct Cost: ¥10,000,000、Indirect Cost: ¥3,000,000)
Fiscal Year 2023: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2022: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2021: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2020: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the immunological differences between HPV-positive and HPV-negative head and neck squamous cell carcinoma (HNSCC) using public database and clinical samples.
HPV-positive HNSCC exhibited higher infiltration of various immune cells and higher expression of cytotoxic-related molecules, suggesting that antitumor immune responses were activated in HPV-positive HNSCC compared to HPV-negative HNSCC. We next evaluated the presence of tumor antigen-specific T cell responses in HPV-positive HNSCC. Blockade of checkpoint pathways could enhance tumor antigen-specific T-cell responses in certain patients, probably via exhausted CD4+T cells. Finally, we examined the relationship between EMT-related gene expression in circulating tumor cells (CTC) and the activation status of peripheral blood T cells. We revealed that SNAI1-high CTCs reflect the antitumor activity of circulating T cells in patients with HPV-positive HNSCC.
|
